DocWire News spoke with Jim Joyce, the co-founder, chairman and CEO of Sigyn Therapeutics, a development technology company that focuses on the treatment of life-threatening inflammation caused by cytokine storm syndrome, a type of The dangerous immune response can be caused by a wide range of infectious and non-communicable diseases, including COVID-19.
Mr. Joyce discussed the benefits of blood purification technology and solved the problem of sepsis, especially in COVID patients.
DocWire News: Can you introduce yourself first?
Jim Joyce: Rob, I have 20 years, actually more than 20 years of leadership experience in listed companies, CEOs and boards. During that time, I have been the inventor of various medical device technologies.
Talk to us about your efforts on Capitol Hill to expand the definition of therapeutic response in the Bioprotection Program legislation.
Of course. Well, the Biological Shield Project, Rob, this is the legislation that started the industry to develop countermeasures against pandemics and bioterrorism threats. This was actually launched in 2005 and has played an important role in countering an increasing number of different threats over the years and has been implemented for events such as COVID-19. But when it was first established, the legislation defined treatment strategies as drugs or vaccines. Therefore, the medical device field we are interested in is excluded from the definition. So we work with a team, which includes myself. My testimony in Congress involves the use of medical equipment to address a wide range of viral pathogens, as well as equipment that can address cytokine storms, which are the cause of many deaths from serious viral infections. Today, at Sigyn Therapeutics, we are advancing a technology that can perform these two functions.
Talk to us about Sigyn Therapeutics-why did you create it and what are the main challenges the company hopes to solve?
Of course. Well, the origin of what we do at Sigyn Therapeutics is based on the background of my co-founder Craig Roberts and I. He participated in the development of the ECMO system, but also developed an additional brain blood purification technology in 22 Approved in several countries for the treatment of life-threatening inflammation. In my previous job myself, as the CEO and founder of the company, I was responsible for overseeing the development of the Athlon blood purifier. This is a therapy. It was the first technology to be designated by the FDA for two breakthrough devices and was deployed as a broad-spectrum countermeasure against the virus threat during the Ebola outbreak, where it was used to save infected doctors Life and was approved to use the regulations here in the United States, Canada, and Germany in emergency situations. But we have consolidated our knowledge base in order to be able to address life-threatening inflammatory conditions associated with pathogen infections. This means that the pathogen sources of inflammation and inflammatory cytokines and other components can be resolved.
How big is the sepsis problem for COVID-19 patients, and how does Sigyn solve this problem?
Well, most patients who die of COVID-19 die of sepsis, and COVID-19 also has this pathogenesis. You will see the progress of pneumonia. Community-acquired pneumonia is an explanation for the conditions that may evolve into ARDS, advanced respiratory distress syndrome, sepsis and septic shock, but in fact, we believe that it is important to be able to intervene quickly and have technology that can be operated quickly. Real-time basis To reduce the circulating presence of inflammatory pathogen sources, and to quickly regulate the production of inflammatory cytokines.
Where will you see your company in three years?
Well, in three years, I think we will have a product that has been proven to save lives. This is our main goal as a company, but it will be realized as a technology when they are available. The advantage of blood purification technology is that it can be combined with drug therapy without adding additional drug toxicity, which should be considered. But in many cases, the types of pathogens we are studying, or the inflammatory conditions we are studying, will trigger this life-threatening cytokine storm. In many cases, it has not been resolved. This will definitely be in the case of COVID-19. This is the case. It is difficult to predict what will happen next. Therefore, you need to have a pan-pathogen technology that can cross the boundaries of different pathogens and resolve inflammatory components like our equipment. I think in this regard, there are signs that our technology can help in the next few years.
There are many types of acute liver failure related to pathogens that cause inflammation, and the same thing is related to pathogens, whether they are bacteria or viruses. Many of these threats have not been resolved with drugs. No, Rob, I am very happy to be able to participate today. I hope people will pay attention to our efforts at Sigyn Therapeutics. We have demonstrated what we think is unprecedented ability to solve pathogens and inflammatory factors, and now we are working hard to translate it into human research.